GB848881A - Improvements in or relating to hormone compositions and the preparation thereof - Google Patents

Improvements in or relating to hormone compositions and the preparation thereof

Info

Publication number
GB848881A
GB848881A GB37651/56A GB3765156A GB848881A GB 848881 A GB848881 A GB 848881A GB 37651/56 A GB37651/56 A GB 37651/56A GB 3765156 A GB3765156 A GB 3765156A GB 848881 A GB848881 A GB 848881A
Authority
GB
United Kingdom
Prior art keywords
give
cyclopentylpropionate
hydroxyprogesterone
acid
succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB37651/56A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB848881A publication Critical patent/GB848881A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

17a -acyloxyprogesterones are made by esterifying 17a -hydroxyprogesterones with an appropriate acid, including monocarboxylic, hydroxy-substituted and di-basic carboxylic acids. The esters may be prepared by dissolving 17a -hydroxyprogesterone in a mixture of the appropriate acid and its anhydride with p toluene sulphonic acid. In alternative methods exemplified for preparing 17a -hydroxyprogesterone cyclopentylpropionate, (6), (a) 17a -hydroxy-progesterone in a methylene chloride / methanol mixture is treated with pyrrolidine to give the pyrrolidinyl enamine which is dissolved in methylene chloride and treated with gaseous HCl to give the hydrochloride. To this is added cyclopentylpropionic acid and cyclopentylpropionyl chloride with p toluene sulphonic acid monohydrate and reacted to give the acyl compound which is purified on a "Florisil" (Registered Trade Mark) column; or (b) 3b , 17a -dihydroxy-5-ene-20-one-3-acetate is esterified with cyclopentylpropionyl chloride to give 3b , 17a -dihydroxy - 5 - ene - 20 - one - 3 - acetone - 17 - cyclopentylpropionate which is treated by methanolic HCl to hydrolyse one-3-acyl group and followed by an Oppenauer oxidation to give 17a -hydroxyprogesterone cyclopentylpropionate. Sodium 17a -hydroxyprogesterone hemi-succinate is prepared (4a) by treating the hemi-succinate with sodium hydroxide. Specifications 784,659, 794,482 and 815,517 are referred to.ALSO:A therapeutic composition for oral administration which produces a progestational effect in humans and animals comprises a 17a -acyloxyprogesterone and a pharmaceutical diluent, or an animal feed mix. The active ingredients are derived from 17a -hydroxy progesterone by esterification with a suitable acid preferably an organic carboxylic acid containing 1 to 12 carbon atoms. Suitable esters are the formate, acetate, propionate, butyrate, iso-butyrate, valerate, enanthate, caproate, caprylate, benzoate cyclopentylpropionate, phenylacetate, phenylpropionate, tri-methylacetate, t-butylacetate, cyclopentylcarboxylate, ethylbutyrate, o-toluate, dodecanoate, cyclohexylacetate, stearate, hydroxystearate, palmitate, gluconate, glucuronate, saccharate, sorbate, ethoxyacetate, furoate, furylacrylate, t-butylphenoxyacetate, p-chlorophenoxyacetate, succinate, glutarate, diglycalate, b -methylglutarate or b ,b -dimethylglutarate and the sodium, potassium, calcium, magnesium and amine salts thereof. Other active ingredients may include other coactive hormonal substances e.g. estrogenic substances such as estradiol &c., or androgenic substances e.g. 17-methyltestosterone &c., analgesics e.g. aspirin, acetyl-p-aminophenol &c., sedatives such as barbiturates, reserpine &c., anti-spasmodics e.g. belladonna, hyoxyamine &c., carticosteroids e.g. carbisone, hydrocortisone, prednisone &c., vitamins e.g. vitamin A, C, D, K and members of the B series, and antibiotics e.g. penicillin, tetracyclines &c. The compositions which are preferably in dosage unit form e.g. tablets, capsules, pills, cachets or pellets, and may also take the form of solutions, syrups, suspensions, emulsions, or elixirs. When prepared in tablet form, different active ingredients may be incorporated in different laminae of which the tablet may be made up, each section may be separated by an enteric coating. The compositions preferably contain from 5-200 mgms of the 17a -acyloxyprogesterone per unit dosage form. Specifications 784,659, 794,482 and 815,517 are referred to.
GB37651/56A 1955-12-27 1956-12-10 Improvements in or relating to hormone compositions and the preparation thereof Expired GB848881A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US848881XA 1955-12-27 1955-12-27

Publications (1)

Publication Number Publication Date
GB848881A true GB848881A (en) 1960-09-21

Family

ID=22187847

Family Applications (1)

Application Number Title Priority Date Filing Date
GB37651/56A Expired GB848881A (en) 1955-12-27 1956-12-10 Improvements in or relating to hormone compositions and the preparation thereof

Country Status (1)

Country Link
GB (1) GB848881A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US8846648B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846649B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Similar Documents

Publication Publication Date Title
GB848881A (en) Improvements in or relating to hormone compositions and the preparation thereof
HU176742B (en) Process for preparing pharmaceutical preparations containing new estradiol-17beta-estres with estrogen activity for oral application
HU176743B (en) Process for preparing combined preparations with anabolic activity for oral application
US4515810A (en) Composition of matter
US3017323A (en) Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics
ES2200978T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDE TRIMEGISTONE.
Colton Steroids and “the pill”: early steroid research at Searle
US3423507A (en) Method of treating benign prostratic hypertrophy
ES484706A1 (en) Corticoid sulfopropionic acid esters and their salts, process for their preparation and pharmaceutical preparations containing these compounds.
US2862921A (en) Erythromycin esters
ES297425A1 (en) Procedure for preparing pharmaceutical compositions in the form of deferred action tablets (Machine-translation by Google Translate, not legally binding)
US3336347A (en) 17alpha-ethinyl-delta1, 3, 5(10)-estratriene-3, 16alpha, 17beta-triol and its estersand ethers
US3514514A (en) 17alpha-ethinyl-18-methyl-19-nortestosterone esters
GB1016959A (en) Substituted steroid hormones
US3231469A (en) beta-benzalbutyramide as an anticholesterolemic agent
JPS6163695A (en) Purimycin salt, manufacture and medicinal composition
US3564049A (en) Adamantane-(1)-carboxylic acid derivatives
KR970704473A (en) DOSAGE STEROID TABLETS CONTAINING GALLIC ACID ESTERS AS ANTIOXIDANT AGENT, PROCESS FOR THE MANUFACTURE OF SAID TABLETS, AND USES OF SAID TABLETS). The present invention relates to low-dosage steroid tablets containing a gallic acid ester as an antioxidant,
US3193457A (en) Oral administration of 6, 16alpha-dimethyl-progesterones
USRE28690E (en) 17α-Ethinyl-18-methyl-19-nortestosterone esters
US2868811A (en) 3beta-acyloxy-17beta-hydroxy-17alpha-ethynyl-5-androstenes and androstanes and theirpreparation
GB1127457A (en) Carboxylic acid-n-methyl-piperazides and process for their manufacture
HU196122B (en) Process for preparing pharmaceuticals comprising 9alpha, 11beta-dichlor-16alpha-methyl-21-(dicyclohexyl-methyloxy-carbonyloxy)-pregno-1,4-dien-3,20-dione
US3415854A (en) Adamantoate esters of 13beta-alkylgon-4-en-3-ols
US3641013A (en) 17beta-hydroxy-18-methyl-4-estrene-3-one and derivatives thereof